Printer Friendly

A SCIENTIFIC BREAKTHROUGH PROVIDES A NEW DELIVERY TECHNOLOGY TO THE BODY CELLS WHICH MAXIMIZES MANY MEDICATIONS

 A SCIENTIFIC BREAKTHROUGH PROVIDES A NEW DELIVERY TECHNOLOGY
 TO THE BODY CELLS WHICH MAXIMIZES MANY MEDICATIONS
 LOS ANGELES, April 14 /PRNewswire/ -- Selected medication may never be the same again following a major scientific breakthrough which gives a wide range of pharmaceutical products new improved delivery technology to the body cells.
 The recently patented technology has strong potential to increase the bio-availability for hundreds of therapeutic compounds and nutritional supplements, such as aspirin, antibiotics, anti- inflammatories, antihistamines and vitamins to name just a few.
 This new delivery technology also has ramifications for HIV positive patients. Documented research by a group of investigators showing that vitamin C inhibits the HIV virus from replicating and subsequently destorying T-cells, can now be taken a step further.
 "The implications for licensing this new technology are highly significant as the pharmacological affects of the selected drugs or nutritional therapies people are currently undergoing may become far more effective. Doses could be decreased therefore lessening toxicity levels or adverse side effects of some therapeutic agents," said the inventor and coordinator of the research, Dick Markham.
 Under Markham's direction, Dr. Anthony Verlangieri, took threonate, a naturally occurring vitamin C metabolite found in the body and added it to a variety of organic acids for evaluation. The research indicated a 50-200 percent absorption increase compared to non-threonate groups in aspirin, the arthritis drug piroxicam and vitamin C.
 Verlangieri, who has published more than 60 recognized papers with more than 100 abstracts, explained that "a threonate-aspirin combination may enable the delivery of an effective dose without the accompanying gastrointestinal side effects."
 Oxycal's Vice President of Operations Nancy Chandler explained how interest quickly sparked throughout the industry but further discussions to license the technology were left pending on a patent being issued by the U.S. Department of Commerce, which has now been granted.
 Verlangieri, who is based at the University of Mississippi's School of Pharmacy, added: "This methodology has provided a new technology in delivering selected therapeutic compounds more efficiently. A decade of research has given Oxycal some very encouraging results.
 "Threonate application facilitates the transport and absorption of the selected compounds at a more efficient and higher rate increasing in blood levels and resulting in the increase in cell levels."
 Oxycal is now seeking to license the technology behind the discovery to various sectors of the pharmaceutical and nutritional worlds.
 One particular and instant area of interest will most likely come from aspirin manufacturers as their product is known to irritate the stomach lining. By combining aspirin with the new delivery technology, the side effects would be instantly lessened.
 "The requirements to get this sort of patent are extremely stringent. There has been no other patent issued which has this kind of effect in increasing absorption and retention," said patent attorney William Drummond.
 Following Verlangieri's extensive medical research he added: "We are on the edge of a new technology for drug delivery. It could become one of the most significant scientific breakthroughs of this century."
 -0- 4/14/92
 /CONTACT: Jonathan Elkins of Pollack PR Marketing Group, 310-556-4443, for Oxycal/ CO: Oxycal ST: California IN: MTC SU:


AL-CH -- LA002 -- 8255 04/14/92 12:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1992
Words:527
Previous Article:RECORD CALLS FLOOD TWA RESERVATIONS CENTERS
Next Article:DATA GENERAL NAMES DEMELLE CHIEF FINANCIAL OFFICER


Related Articles
GENE THERAPY COMPANIES SEEK TO MERGE
TECHNOLOGICAL BREAKTHROUGH IN VACCINE DEVELOPMENT; RESEARCHERS ALIGNED WITH CHICAGO BIOTECH FIRM DISCUSS POTENTIAL
Priority Pharmacy Selected as Nationwide Distributor for New Breakthrough AIDS Drug Serostim(TM)
Human Stem Cell Breakthrough Heralds New Era of 'Gero-Technology'.
Sangart patents blood substitute.
Revolutionary Technology Offers New Hope for Treating Chronic Pain; Boston Scientific announces nationwide release of world's smallest and first...
The World's First Commercially-Licensed Gene Therapy Drug Produced in NBS CelliGen Plus(R) Packed-Bed Bioreactor.
Milestone Scientific Inc. Announces Patent Protection On Two Critical Elements of Its CompuFlo(TM) Technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters